| HPR180 eligibility of orphan drugs for preferential reimbursement in Egypt AN Fasseeh, B Elezbawy, N Korra, M Roushdy, A Seyam, N Hayek, ... Value in Health 25 (12), S265, 2022 | 2 | 2022 |
| Institutionalizing health technology assessment in Egypt: situational analysis and roadmap P Pinilla-Dominguez, S Taha, H McGuire, A Elagamy, A Sedrak, M Gamal, ... Frontiers in Pharmacology 13, 1014658, 2022 | 2 | 2022 |
| HTA341 Egyptian Guidelines for Pharmacoeconomic Evaluations: Toward Standardization of Drug Reimbursement Applications M Roushdy, G Elsisi, AS Sedrak, A Elagamy, A Seyam, M Eldebeiky, ... Value in Health 26 (12), S386, 2023 | | 2023 |
| Maximizing the benefits of using biosimilars in Egypt AN Fasseeh, B Elezbawy, KA El-Fass, M GamaI, A Seyam, N Hayek, ... Journal of Pharmaceutical Policy and Practice 16 (1), 79, 2023 | | 2023 |
| Redesigning Price Setting under the Universal Health Insurance in Egypt/إعادة تصميم التسعير في ظل التأمين الصحي الشامل في مصر A El Agamy, HA Ismail, H Hassan, R Gouda, S El Sayed | | 2022 |
